What's Happening?
Delphi Diagnostics has announced the publication of new clinical data in the European Journal of Cancer, validating the Endocrine Activity Index Recurrence Risk (EAIRR) as a significant independent predictor of outcomes in patients with hormone receptor-positive,
node-positive breast cancer. The study analyzed 659 patient samples from the PACS-01 clinical trial, demonstrating that EAIRR provides meaningful prognostic and endocrine-predictive information beyond the 21-gene Recurrence Score. This validation establishes EAIRR as a differentiated biomarker that captures endocrine biology, which is crucial for long-term outcomes in breast cancer. Delphi Diagnostics, based in Texas, holds an exclusive license from The University of Texas MD Anderson Cancer Center to commercialize this technology.
Why It's Important?
The validation of EAIRR as a prognostic tool is significant for the field of oncology, particularly in the treatment of breast cancer. By providing additional prognostic information beyond existing tests, EAIRR can help refine risk stratification and personalize treatment plans for patients. This advancement could lead to more targeted and effective therapies, potentially improving survival rates and quality of life for breast cancer patients. The ability to predict which patients will benefit from endocrine therapy can also optimize treatment regimens, reducing unnecessary exposure to chemotherapy and its associated side effects.
What's Next?
Delphi Diagnostics aims to make the EAIRR test widely available to breast cancer patients, opening new pathways for personalized treatment. The company will likely focus on further clinical validation and regulatory approval processes to integrate this tool into standard care practices. As the healthcare industry continues to move towards personalized medicine, tools like EAIRR could become integral in tailoring treatments to individual patient profiles, potentially influencing future research and development in oncology.
